2023 MASCC/ESMO共识建议:放疗和放化疗引起的恶心和呕吐的预防(更新版)

2023-12-15 欧洲肿瘤内科学会 Support Care Cancer 发表于上海

放疗和放化疗引起的恶心和呕吐(RINV和C-RINV)临床常见,本文主要MASCC/ESMO关于RINV和C-RINV的止吐指南提供更新建议。

中文标题:

2023 MASCC/ESMO共识建议:放疗和放化疗引起的恶心和呕吐的预防(更新版)

英文标题:

2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting

发布机构:

欧洲肿瘤内科学会

发布日期:

2023-12-15

简要介绍:

放疗和放化疗引起的恶心和呕吐(RINV和C-RINV)临床常见,本文主要MASCC/ESMO关于RINV和C-RINV的止吐指南提供更新建议。
 

相关资料下载:
[AttachmentFileName(sort=1, fileName=2023 MASCC_ESMO共识建议:放疗和放化疗引起的恶心和呕吐的预防(更新版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=5ab131c003a9084d, title=2023 MASCC/ESMO共识建议:放疗和放化疗引起的恶心和呕吐的预防(更新版), enTitle=2023 Updated MASCC/ESMO Consensus Recommendations: prevention of radiotherapy- and chemoradiotherapy-induced nausea and vomiting, guiderFrom=Support Care Cancer, authorId=0, author=, summary=放疗和放化疗引起的恶心和呕吐(RINV和C-RINV)临床常见,本文主要MASCC/ESMO关于RINV和C-RINV的止吐指南提供更新建议。, cover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Fri Dec 15 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<div class="guideDetailsCont flex-row-between-start" style="color: #333333;"> <div class="detailsContRight" style="color: #222222;">放疗和放化疗引起的恶心和呕吐(RINV和C-RINV)临床常见,本文主要MASCC/ESMO关于RINV和C-RINV的止吐指南提供更新建议。</div> </div> <div class="detailsQRWrapper" style="color: #333333;"> <div id="app_detail" class="detailsQR" title="https://m.medlive.cn/guide/1/30575">&nbsp;</div> </div>, tagList=[TagDto(tagId=3855, tagName=化疗相关恶心呕吐)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=3855, articleKeyword=化疗相关恶心呕吐, articleKeywordNum=6, guiderKeywordId=3855, guiderKeyword=化疗相关恶心呕吐, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=651, appHits=21, showAppHits=0, pcHits=117, showPcHits=630, likes=1, shares=2, comments=2, approvalStatus=1, publishedTime=Mon Dec 18 17:05:00 CST 2023, publishedTimeString=2023-12-15, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Dec 18 11:24:27 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Sat Jan 06 20:38:53 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 MASCC_ESMO共识建议:放疗和放化疗引起的恶心和呕吐的预防(更新版).pdf)])
2023 MASCC_ESMO共识建议:放疗和放化疗引起的恶心和呕吐的预防(更新版).pdf
下载请点击:
评论区 (1)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2175687, encodeId=98f221e568730, content=有收获, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43cf4813674, createdName=632486667, createdTime=Mon Dec 18 21:16:21 CST 2023, time=2023-12-18, status=1, ipAttribution=浙江省)]
    2023-12-18 632486667 来自浙江省

    有收获

    0

拓展阅读

eClinicalMed:阿瑞匹坦联合帕洛诺司琼预防化疗诱发性呕吐的效果

阿瑞匹坦联合帕洛诺司琼预防化疗引起的呕吐的效果明显优于地塞米松联合帕洛诺司琼

对一大串癌症及治疗相关症状束手无策?请“老祖宗”出手帮忙!

Journal of Cancer:针灸与电针在治疗癌症相关症状及副作用的应用。

奥氮平可对抗化疗引起的恶心呕吐

即将在芝加哥召开的美国临床肿瘤学会(ASCO)年会会前新闻会上报告的一项临床试验表明,抗精神病药物奥氮平治疗突破性化疗引起的恶心呕吐(CINV)优于标准治疗药物胃复安,该结果将有望改变某些癌症患者治疗方案。   在这项双盲III期试验中,印第安纳大学哈珀癌症研究所所长Rudolph M. Navari博士及其同事招募了接受高致吐性化疗药物(顺铂>70 mg/m2、阿霉素>

加拿大临床实践指南:预防小儿癌症患者急性和延迟化疗引起的恶心和呕吐

安大略省儿科肿瘤研究组(POGO,Pediatric Oncology Group of Ontario) · 2022-10-11

2023 MASCC/ESMO指南:化疗和放疗引起的恶心和呕吐的预防(更新版)

癌症支持疗法多国学会(MASCC,Multinational Association of Supportive Care in Cancer) · 2024-01-11